CPTech Documents

• May, 2006. James Love. Bulletin of the World Health Organization. 84 (5). Drug development incentives to improve access to essential medicines.
• February 24, 2005. Sign on letter to the World Health Organizations's Commission on Intellectual Property, Innovation and Health The letter asks the Commission to evaluate a new treaty framework for medical R&D.
• February 7, 2005. Draft Version 4 of the proposed Medical Research and Development Treaty.
• July 22, 2004. Consumer Project on Technology, Consumers Union, Consumer Federation of America, Health Action International, Essential Action, and Consumer Action. Joint letter to US Trade Representative Robert Zoellick.
• July 1, 2004 CPTech comments on US Department of Commerce, DHHS and USTR Study of International Drug Pricing, proposing R&D+ as alternative trade framework.
• June, 2004. James Love and Tim Hubbard in Bridges. Make Drugs Affordable: Replace TRIPs-plus by R&D-plus.
• March 4, 2004. Op-ed by James Love and Tim Hubbard published in the Guardian. We're Patently Going Mad: Lifesaving drugs must be developed differently - for all our sakes. Here is James V. Delong's rather rambling attack on the Guardian article, which links quite a few different issues, proposals and movements into one.
• February 2, 2004. Essay by James Love and Tim Hubbard published in the PLoS Biology. A New Trade Framework for Global Healthcare R&D.
• December 4, 2003. Paper presentend by James Love at Columbia University's Workshop on Access to Medicines and the Financing of Innovations in Heath Care. A New Trade Framework for Global Healthcare R&D. Also, see the Conference Home Page.
• July 7, 2003. Letter from 63 experts and stakeholdedras to Kamil Idris, Director-General of WIPO, requesting that WIPO host a meeting on open collaborative development models. Available in PDF format and plain text.
• June 24, 2003. Tim Hubbard and James Love. Paper presented at the Meeting on The Role of Generics and Local Industry in Attaining the Millennium Development Goals (MDGs) in Pharmaceuticals and Vaccines held at the World Bank. An Agenda for Research and Development.
• June 14, 2003. Tim Hubbard and James Love in the New Scientist. Medicines without barriers.
• May 27, 2003 James Love. From TRIPS to RIPS: A better Trade Framework to support Innovation in Medical Technologies. (MS Word format) Presented at the Workshop on Economic issues related to access to HIV/AIDS care in developing countries, Agence nationale de recherches sur le sida, Marsielle, France.
• April 29, 2003. James Love. Presentation at the Meeting on global framework for supporting health research and development (R&D) in areas of market and public policy failure, Geneva, Switzerland. Basis for a treaty on R&D.
• December 3, 2002. James Love. PPT presentation given at The Drugs for Neglected Diseases (DND) Working Group, in Rio de Janerio, Brazil. The Benifits of a Treaty on R&D.
• CPTech Page on Request for WIPO Meeting on Collaborative Development Models
• Open Develpment Models for Medical and Scientific Research.

Other Documents

• WTO Documents
  • Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS)
  • Declaration on the TRIPS Agreement and Public Health.
• WHO Documents
  • May 28, 2003. 56th World Health Assembly Resolution 27. Intellectual property rights, innovation and public health.
  • Special Programme for Research and Training in Tropical Diseases (TDR).

• July 26, 2005. Professor Luigi Ortenigo of Brescia University. Comments on the Proposed Medical R&D Treaty.
• February 22, 2005. Nicoletta Dentico and Nathan Ford, from the MSF Neglected Disease Group. Article published in PLoS Medicine. The Courage to Change the Rules: A Proposal for an Essential Health R&D Treaty.
• September 22, 2004. Dean Baker, Center for Economic and Policy Research. Financing Drug Research: What Are the Issues?"
• June 25, 2004. Joseph A. DiMasi and Henry G. Grabowski. Patents and R&D Incentives: Comments on the Hubbard and Love Trade Framework for Financing Pharmaceutical R&D.
• November 12, 2003. John Barton. Preserving the Global Scientific and Technological Commons.
• September 25, 2003. Mark B McClellan, Commissioner of the US Food and Drug Administration. Speech before the First International Colloquium on Generic Medicine.
• September 19, 2003. David Dickson for the Science and Development Network. Cancún's failure raises need for collaborative science.
• July 10, 2003. Declan Butler for Nature, vol 424. Drive for patent-free innovation gathers pace. Text of story on www.nature.com (password required), or click here for the version on the ip-health archives.

• October 30, 2003. William Steiger, US Department of Health and Human Services, letter to the World Health Organziation ( bit mapped image of letter , ocr image of letter) setting out US government views on the terms of reference and membership of the proposed commission on innovation, Intellectual Property Rights and public health. (CIPIH) This document provided an aggressive defensive of the strong IPR model for financing innovative, rejecting suggestions for more focus on open medicine models, open journals, R&D treaties or other non-proprietary models. Some quotes from the memo follow:

  "The body should not be engaged in considering amendment to existing international legal or trade instruements or new instruments such as an international research and development (R&D) treaty.

  "In contrast, the current thinking of many non-government organizations (NGOs) is that there neeeds to be an expansion of "open source" research. Non-proprietary research, however, generally does not stimulate the intensive investment necessary to transform basic technologies into innovative products because there is no prospect of exclusivity to reward the risk of devoting scare capital to product development. . .

  "In particularly,the group should consider new incentives that stimulate research for priority diseases of developing countries to broaden the beneficiaries of biomedical innovation, including models such as transferable rights of market exclusivity. . .

  "Much recent discussion has been generated on the need to provide free access to medical jouranls to research communities in developing countries as a way of bridging the health information gap. Much of this information is already available--for developed and developing countries alike--in no-cost (free) databases, including patent databases easily accessible on the Internet. . . . An anti-patent policy ensures that valuable research and technology know-how is not patented, and is therefore not disclosed to the public.

Op-Ed Columns on Trade and Research

• May 3, 2005. Priya Shetty for SciDev.net. More creative thinking needed on drug R&D.
• March 1, 2005. Eva Tallaksen for SciDev.net. World 'needs global R&D health treaty.'
• June 21, 2004. Susan Warner for the Scientist. Let Them Eat Protease Inhibitors - Charities want to reshape the global drug development system to provide treatments to people in poor countries.
• May 18, 2004. James V. Delong for TechCentral Staation. Peddling Dope: Open Source Drug Development.
• November 6, 2003. Charles Brendon in the Oxford Student. Patently Misanthropic: Can We Make Drugs Affordable for the Third World?
• August 22, 2003. Burton Weisbrod's op-ed in the Washington Post. Solving the Drug Dilemma.
• July, 2003. German Velasquez for Le Monde. Unhealthy Profits.

News Stories

• March 25, 2005. European Commission website's news. Call for global R&D health treaty resonates loudly.
• February 25, 2005. Andrew Jack for the Financial Times. WHO members urged to sign Kyoto-style medical treaty.

Neglected Diseases - Diseases for which there is Little or No Research

• MSF Page on Neglected Diseases
• CPTech Page on Neglected Diseases
• CPTech Page on R&D
• Global Forum for Health Research Page on "Closing the 10/90 Funding Gap."
• September 16, 2003. Journal of the Canadian Medical Association. MSF Nonprofit Drug Company Launched.
• September 12, 2003. Zina Moukheiber for Forbes. Protecting The Orphan Drugs.